369 related articles for article (PubMed ID: 36066745)
1. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis.
Gwaltney C; Ivanescu C; Karlsson L; Warholic N; Kjems L; Horn P
Adv Ther; 2022 Nov; 39(11):5105-5125. PubMed ID: 36066745
[TBL] [Abstract][Full Text] [Related]
2. Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver Diseases.
Gwaltney C; Bean S; Venerus M; Karlsson L; Warholic N; Kjems L; Horn P
Adv Ther; 2022 Nov; 39(11):5126-5143. PubMed ID: 36066744
[TBL] [Abstract][Full Text] [Related]
3. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
Thompson RJ; Arnell H; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Durmaz Ö; Fischler B; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Kjems L; Lacaille F; Lachaux A; Lainka E; Mack CL; Mattsson JP; McKiernan P; Özen H; Rajwal SR; Roquelaure B; Shagrani M; Shteyer E; Soufi N; Sturm E; Tessier ME; Verkade HJ; Horn P
Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):830-842. PubMed ID: 35780807
[TBL] [Abstract][Full Text] [Related]
4. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis.
Thompson RJ; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Di Giorgio A; Durmaz Ö; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Lacaille F; Lachaux A; Lainka E; Loomes KM; Mack CL; Mattsson JP; McKiernan P; Ni Q; Özen H; Rajwal SR; Roquelaure B; Shteyer E; Sokal E; Sokol RJ; Soufi N; Sturm E; Tessier ME; van der Woerd WL; Verkade HJ; Vittorio JM; Wallefors T; Warholic N; Yu Q; Horn P; Kjems L
JHEP Rep; 2023 Aug; 5(8):100782. PubMed ID: 37456676
[TBL] [Abstract][Full Text] [Related]
5. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Baumann U; Sturm E; Lacaille F; Gonzalès E; Arnell H; Fischler B; Jørgensen MH; Thompson RJ; Mattsson JP; Ekelund M; Lindström E; Gillberg PG; Torfgård K; Soni PN
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101751. PubMed ID: 34182185
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Psychometric Validation of the ViSIO-PRO and ViSIO-ObsRO in Retinitis Pigmentosa and Leber Congenital Amaurosis.
Fischer MD; Patalano F; Naujoks C; Banhazi J; Bouchet C; O'Brien P; Kay C; Green J; Durham T; Bradley H; Williamson N; Barclay M; Sims J; Audo I
Ophthalmol Ther; 2023 Apr; 12(2):1359-1386. PubMed ID: 36847938
[TBL] [Abstract][Full Text] [Related]
8. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
9. Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis.
Slavetinsky C; Sturm E
BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32601135
[TBL] [Abstract][Full Text] [Related]
10. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Miethke AG; Moukarzel A; Porta G; Covarrubias Esquer J; Czubkowski P; Ordonez F; Mosca A; Aqul AA; Squires RH; Sokal E; D'Agostino D; Baumann U; D'Antiga L; Kasi N; Laborde N; Arikan C; Lin CH; Gilmour S; Mittal N; Chiou FK; Horslen SP; Huber WD; Jaecklin T; Nunes T; Lascau A; Longpre L; Mogul DB; Garner W; Vig P; Hupertz VF; Gonzalez-Peralta RP; Ekong U; Hartley J; Laverdure N; Ovchinsky N; Thompson RJ
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):620-631. PubMed ID: 38723644
[TBL] [Abstract][Full Text] [Related]
11. Psychometric Evaluation of a New Patient-Reported Outcome (PRO) Symptom Diary for Varicose Veins: VVSymQ(®) Instrument.
Wright DD; Paty J; Turner-Bowker DM; Bradbury A
Patient; 2016 Aug; 9(4):335-48. PubMed ID: 27016239
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
Ovchinsky N; Aumar M; Baker A; Baumann U; Bufler P; Cananzi M; Czubkowski P; Durmaz Ö; Fischer R; Indolfi G; Karnsakul WW; Lacaille F; Lee WS; Maggiore G; Rosenthal P; Ruiz M; Sokal E; Sturm E; van der Woerd W; Verkade HJ; Wehrman A; Clemson C; Yu Q; Ni Q; Ruvido J; Manganaro S; Mattsson JP
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):632-645. PubMed ID: 38670135
[TBL] [Abstract][Full Text] [Related]
13. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
[TBL] [Abstract][Full Text] [Related]
14. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
Silverberg JI; Leshem YA; Calimlim BM; McDonald J; Litcher-Kelly L
Curr Med Res Opin; 2023 Oct; 39(10):1289-1296. PubMed ID: 37691437
[TBL] [Abstract][Full Text] [Related]
15. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
[TBL] [Abstract][Full Text] [Related]
16. [Validation of the QFS measuring the frequency and satisfaction in social behaviours in psychiatric adult population].
Zanello A; Weber Rouget B; Gex-Fabry M; Maercker A; Guimon J
Encephale; 2006; 32(1 Pt 1):45-59. PubMed ID: 16633290
[TBL] [Abstract][Full Text] [Related]
17. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
Gottlieb AB; Warren RB; Augustin M; Garcia L; Cioffi C; Peterson L; Pelligra C; Ciaravino V
Adv Ther; 2021 Oct; 38(10):5253-5269. PubMed ID: 34471992
[TBL] [Abstract][Full Text] [Related]
18. [Caregiver burden in relatives of persons with schizophrenia: an overview of measure instruments].
Reine G; Lancon C; Simeoni MC; Duplan S; Auquier P
Encephale; 2003; 29(2):137-47. PubMed ID: 14567165
[TBL] [Abstract][Full Text] [Related]
19. Odevixibat: First Approval.
Deeks ED
Drugs; 2021 Oct; 81(15):1781-1786. PubMed ID: 34499340
[TBL] [Abstract][Full Text] [Related]
20. Psychometric Validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB).
Brod M; Rasmussen MH; Alolga S; Beck JF; Bushnell DM; Lee KW; Maniatis A
Pharmacoecon Open; 2023 Jan; 7(1):121-138. PubMed ID: 36255609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
